Comparative effects of different cellulosic-based directly compressed orodispersable tablets on oral bioavailability of famotidine

被引:42
作者
Abdelbary, A. [1 ]
Elshafeey, A. H. [1 ]
Zidan, G. [2 ]
机构
[1] Cairo Univ, Fac Pharm, Coll Pharm, Pharmaceut & Ind Pharm Dept, Cairo, Egypt
[2] Misr Int Univ, Dept Pharmaceut, Cairo, Egypt
关键词
Orodispersable tablets; Famotidine; L-HPC; Mannitol; Ac-Di-Sol; Bioavailability; DISINTEGRATION; FORMULATION;
D O I
10.1016/j.carbpol.2009.02.030
中图分类号
O69 [应用化学];
学科分类号
070301 [无机化学];
摘要
Famotidine is a potent H-2-receptor antagonist most commonly used by elderly patients. Orodispersible tablets (ODT) are gaining popularity over conventional tablets due to their convenience and suitability for patients having dysphagia. The purpose of this study is to prepare famotidine ODT using the economic direct-compression method. A 3(2) full factorial design was used to evaluate the influence of different excipients on the properties and in vitro dissolution of famotidine ODT. Two factors were studied for their qualitative effects, namely, disintegrants and diluents. Disintegrants were studied in three levels viz. Ac-Di-Sol, sodium starch glycolate (Primojel) and low-substituted hydroxypropyl cellulose (L-HPC). Fillers were studied in three levels viz. mannitol, spray dried lactose and Avicel PH 101. The ODTs were prepared by direct compression and were evaluated for hardness, drug content. uniformity of weight, in vitro disintegration time, oral disintegration time, wetting time and in vitro dissolution. Maximum dissolution and minimum oral disintegration time (11.4 s) were observed in F7 prepared using L-HPC and mannitol. Furthermore, in human volunteers it showed significant increase in bioavailability compared to Servipep(R) with mean AUC((0-infinity)) 117.1 ng/ml and 82.71 ng/ml, respectively, and its relative bioavailability was 141.57%. Hence, ODT (177) could possibly be used to overcome the drawbacks of conventional famotidine tablets in elderly patients with significant increase in oral bioavailability. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:799 / 806
页数:8
相关论文
共 18 条
[1]
Bi YX, 1996, CHEM PHARM BULL, V44, P2121
[2]
Cousin G, 1995, US Patent, Patent No. 5464632
[3]
DOLLERY C, 1999, THERAPEUTIC DRUGS, pF14
[4]
Development of fast disintegrating compressed tablets using amino acid as disintegratation accelerator: Evaluation of wetting and disintegration of tablet on the basis of surface free energy [J].
Fukami, J ;
Ozawa, A ;
Yoshihashi, Y ;
Yonemochi, E ;
Terada, K .
CHEMICAL & PHARMACEUTICAL BULLETIN, 2005, 53 (12) :1536-1539
[5]
GILBERT SB, 2002, MODERN PHARM, P683
[6]
Green R., 1999, US Patent 5 976 577, Patent No. 5976577
[7]
Mendes RW, 1990, ENCY PHARM TECHNOLOG, V2, P397
[8]
Michael He Min, 2002, United States Patent, Patent No. 6465009
[9]
Spray dried excipient base: A novel technique for the formulation of orally disintegrating tablets [J].
Mishra, DN ;
Bindal, M ;
Singh, SK ;
Kumar, SGV .
CHEMICAL & PHARMACEUTICAL BULLETIN, 2006, 54 (01) :99-102
[10]
Formulation design of an oral, fast-disintegrating dosage form containing taste-masked particles of famotidine [J].
Mizumoto, Takao ;
Tamura, Tetsuya ;
Kawai, Hitoshi ;
Kajiyama, Atsushi ;
Itai, Shigeru .
CHEMICAL & PHARMACEUTICAL BULLETIN, 2008, 56 (07) :946-950